These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 8962111)
1. Oncogenic mutation in the Kit receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP-1. Piao X; Paulson R; van der Geer P; Pawson T; Bernstein A Proc Natl Acad Sci U S A; 1996 Dec; 93(25):14665-9. PubMed ID: 8962111 [TBL] [Abstract][Full Text] [Related]
2. Specificity of the SH2 domains of SHP-1 in the interaction with the immunoreceptor tyrosine-based inhibitory motif-bearing receptor gp49B. Wang LL; Blasioli J; Plas DR; Thomas ML; Yokoyama WM J Immunol; 1999 Feb; 162(3):1318-23. PubMed ID: 9973385 [TBL] [Abstract][Full Text] [Related]
3. The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit. Pedersen M; Rönnstrand L; Sun J Cell Signal; 2009 Mar; 21(3):413-8. PubMed ID: 19049823 [TBL] [Abstract][Full Text] [Related]
4. Phosphatidylinositol 3'-kinase is required for growth of mast cells expressing the kit catalytic domain mutant. Shivakrupa R; Bernstein A; Watring N; Linnekin D Cancer Res; 2003 Aug; 63(15):4412-9. PubMed ID: 12907613 [TBL] [Abstract][Full Text] [Related]
5. Leptin receptor activation of SH2 domain containing protein tyrosine phosphatase 2 modulates Ob receptor signal transduction. Li C; Friedman JM Proc Natl Acad Sci U S A; 1999 Aug; 96(17):9677-82. PubMed ID: 10449753 [TBL] [Abstract][Full Text] [Related]
6. SHP-1 binds and negatively modulates the c-Kit receptor by interaction with tyrosine 569 in the c-Kit juxtamembrane domain. Kozlowski M; Larose L; Lee F; Le DM; Rottapel R; Siminovitch KA Mol Cell Biol; 1998 Apr; 18(4):2089-99. PubMed ID: 9528781 [TBL] [Abstract][Full Text] [Related]
7. A point mutation in the catalytic domain of c-kit induces growth factor independence, tumorigenicity, and differentiation of mast cells. Piao X; Bernstein A Blood; 1996 Apr; 87(8):3117-23. PubMed ID: 8605325 [TBL] [Abstract][Full Text] [Related]
8. Necessity of tyrosine 719 and phosphatidylinositol 3'-kinase-mediated signal pathway in constitutive activation and oncogenic potential of c-kit receptor tyrosine kinase with the Asp814Val mutation. Hashimoto K; Matsumura I; Tsujimura T; Kim DK; Ogihara H; Ikeda H; Ueda S; Mizuki M; Sugahara H; Shibayama H; Kitamura Y; Kanakura Y Blood; 2003 Feb; 101(3):1094-102. PubMed ID: 12393643 [TBL] [Abstract][Full Text] [Related]
9. Signalling by the W/Kit receptor tyrosine kinase is negatively regulated in vivo by the protein tyrosine phosphatase Shp1. Paulson RF; Vesely S; Siminovitch KA; Bernstein A Nat Genet; 1996 Jul; 13(3):309-15. PubMed ID: 8673130 [TBL] [Abstract][Full Text] [Related]
10. Genetic evidence that Shp-2 tyrosine phosphatase is a signal enhancer of the epidermal growth factor receptor in mammals. Qu CK; Yu WM; Azzarelli B; Feng GS Proc Natl Acad Sci U S A; 1999 Jul; 96(15):8528-33. PubMed ID: 10411909 [TBL] [Abstract][Full Text] [Related]
11. A change in structural integrity of c-Kit mutant D816V causes constitutive signaling. Raghav PK; Singh AK; Gangenahalli G Mutat Res; 2018 Mar; 808():28-38. PubMed ID: 29482074 [TBL] [Abstract][Full Text] [Related]
12. Abnormal mesoderm patterning in mouse embryos mutant for the SH2 tyrosine phosphatase Shp-2. Saxton TM; Henkemeyer M; Gasca S; Shen R; Rossi DJ; Shalaby F; Feng GS; Pawson T EMBO J; 1997 May; 16(9):2352-64. PubMed ID: 9171349 [TBL] [Abstract][Full Text] [Related]
13. Establishment and characterization of pro-B cell lines from motheaten mutant mouse defective in SHP-1 protein tyrosine phosphatase. Miyamoto A; Kunisada T; Yamazaki H; Miyake K; Nishikawa SI; Sudo T; Shultz LD; Hayashi SI Immunol Lett; 1998 Sep; 63(2):75-82. PubMed ID: 9761368 [TBL] [Abstract][Full Text] [Related]
14. The D816V mutation of c-Kit circumvents a requirement for Src family kinases in c-Kit signal transduction. Sun J; Pedersen M; Rönnstrand L J Biol Chem; 2009 Apr; 284(17):11039-47. PubMed ID: 19265199 [TBL] [Abstract][Full Text] [Related]
15. The Shp-2 tyrosine phosphatase activates the Src tyrosine kinase by a non-enzymatic mechanism. Walter AO; Peng ZY; Cartwright CA Oncogene; 1999 Mar; 18(11):1911-20. PubMed ID: 10208413 [TBL] [Abstract][Full Text] [Related]
16. The tyrosine phosphatase SHP-2 is required for mediating phosphatidylinositol 3-kinase/Akt activation by growth factors. Wu CJ; O'Rourke DM; Feng GS; Johnson GR; Wang Q; Greene MI Oncogene; 2001 Sep; 20(42):6018-25. PubMed ID: 11593409 [TBL] [Abstract][Full Text] [Related]
17. Regulation of angiotensin II-induced JAK2 tyrosine phosphorylation: roles of SHP-1 and SHP-2. Marrero MB; Venema VJ; Ju H; Eaton DC; Venema RC Am J Physiol; 1998 Nov; 275(5):C1216-23. PubMed ID: 9814969 [TBL] [Abstract][Full Text] [Related]
18. The major SHP-1-binding, tyrosine-phosphorylated protein in macrophages is a member of the KIR/LIR family and an SHP-1 substrate. Berg KL; Carlberg K; Rohrschneider LR; Siminovitch KA; Stanley ER Oncogene; 1998 Nov; 17(19):2535-41. PubMed ID: 9824165 [TBL] [Abstract][Full Text] [Related]
19. Novel thiazole amine class tyrosine kinase inhibitors induce apoptosis in human mast cells expressing D816V KIT mutation. Jin Y; Ding K; Wang D; Shen M; Pan J Cancer Lett; 2014 Oct; 353(1):115-23. PubMed ID: 25088577 [TBL] [Abstract][Full Text] [Related]
20. Fyn kinase acts upstream of Shp2 and p38 mitogen-activated protein kinase to promote chemotaxis of mast cells towards stem cell factor. Samayawardhena LA; Hu J; Stein PL; Craig AW Cell Signal; 2006 Sep; 18(9):1447-54. PubMed ID: 16442778 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]